Key facts
- It has raised $160K; the latest was Early Stage VC in Sep 2025.
- Notable investors include Venture Kick, Kickfund, Wyss Zurich.
- Status: Privately Held (backing).
Investors
3- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Tandem Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Tandem Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Tandem Therapeutics
Operator of a biopharmaceutical company intended to bring extracellular matrix targeting to the forefront of fibrotic disease treatments. The company specializes in advancing research in extracellular matrix biology and its role in fibrotic diseases, including cancers and organ fibrosis, offering a novel therapeutic approach through Matrix Targeting Peptides (MTP), helping patients suffering from fibrotic conditions by providing a more precise and effective treatment option.
- Sector
- Healthcare
- HQ
- Schlieren, Switzerland
- Founded
- 2023
- Employees
- 5
- Website
- tandem-tx.com/
- Ownership
- Privately Held (backing)
Tandem Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Tandem Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Tandem Therapeutics in its N-PORT filings yet. We sweep new filings monthly.